SAN DIEGO, April 12, 2017 /PRNewswire/ --
The Company’s small molecule drug program is aimed at treating cancer and autoimmune diseases
As previously reported, Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) has completed the first phase of its small molecule optimization program, which involved synthesizing more than 40 analogues of its initial lead compounds (RG-NA01, RG-NA02, RG-NI01 and RG-NI02). The compounds synthesized consist of activators (RG-NA01 and RG-NA02) and inhibitors (RG-NI01 and RG-NI02) of NR2F6 and were identified using Regen’s patented screening methodology and unique chemical libraries.
With the crucial first phase completed the Company, along with ChemDiv, Inc. (the contract research organization conducting these studies on behalf of Regen BioPharma), can move forward with the optimization process, which involves introducing the synthesized compound analogues to cells specifically designed to respond to NR2F6 agonists and learning more about their potency.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient’s own immune system, as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity (e.g.: arthritis).
“The ChemDiv team has synthesized more than 40 analogues of our initial small molecules and has begun screening them for activity. We are excited that several of these compounds have dose-dependent activity in our cellular assay,” says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. “We are currently evaluating the relationship between the structure of the compounds and their activity. By performing careful and thoughtful medicinal chemistry, we expect to be in a strong position in a few months, in terms of having a well-understood optimized activator and inhibitor of NR2F6.”
David Koos, PhD, Regen BioPharma’s Chairman & CEO noted, “We have identified compounds that will likely cause the body’s own immune system to fight cancer and autoimmune diseases, such as arthritis, by manipulating the immune checkpoint NR2F6. A key differentiator for Regen is being able to deliver these therapies through small molecule treatments (e.g.: pill form), which should produce an easier and more comfortable approach for patients, leading to fewer and less severe side effects than currently used therapies.”
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
SOURCE Regen BioPharma, Inc.
